Onxeo is a biotechnology company, that develops drugs for the treatment of orphan oncology diseases worldwide. The Company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops Beleodaq for the treatment of others liquid or solid tumors; AsiDNA, which is in Phase I clinical trial for the treatment of metastatic melanoma; Livatag that is in Phase III clinical trial to treat advanced primary liver cancer; and Validive, which is in Phase II clinical trial for the treatment of serious mucositis in patients treated for a head and neck cancer.